Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Neurologix Inc (NRGXQ)

Neurologix Inc (NRGXQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Neurologix Inc ONE BRIDGE PLAZA FORT LEE NJ 07024 USA

www.neurologix.net P: 201-592-6451

Description:

Neurologix, Inc. primarily focuses on the development of a therapeutic product to meet the needs of patients suffering from Parkinson's disease. The Company's development efforts are focused on gene transfer for treating Parkinson's disease. Its core technology, which it refers to as NLX, is in the clinical development stages, and tested in the Phase I and Phase II clinical trials to treat Parkinson's disease. Neurologix also focuses on developing therapies to treat other neurodegenerative and metabolic disorders, including therapies relating to epilepsy, Huntington's disease, and depression, as well as metabolic disorders, including genetically-based obesity. Its treatments are designed as alternatives to conventional surgical and pharmacological treatments. In October 2006, the Company completed its Phase I clinical trial of gene transfer for Parkinson's disease. In November 2009, the Company completed 44 of the planned surgeries associated with the Phase II clinical trial.

Key Statistics

Overview:

Market Capitalization, $K 20
Shares Outstanding, K 28,000
Annual Sales, $ 0 K
Annual Net Income, $ 0 K
60-Month Beta 13.10
% of Insider Shareholders 18.43%
% of Institutional Shareholders 0.00%

Growth:

1-Year Return 40.00%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 06/30/14
Earnings Per Share ttm 0.00
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

NRGXQ Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 0.00
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar